Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Fumihiro Ozaki

Keiji Ishibashi

Yasuhiro Kabasawa

Norio Minami

Toshiaki Ogawa

Hideyuki Adachi

Takanori Kawamura

Hiroki Ishihara

Hiroshi Katoh

Toshihiko Kaneko

Shigeru Souda

Hitoshi Oinuma

Kazuki Miyazaki

Atsushi Kamada

Nobuyuki Mori

Takashi Hasegawa

Kohtarou Kodama

Kiyoaki Kobayashi

Nobuhisa Watanabe

Itaru Tsukada

Yoshihiko Norimine

Kohei Sawada

Yoshimitsu Naoe

Takashi Yoshinaga

Megumi Ikemori

Tatsuhiro Onogi

Hiroyuki Suzuki

Koki Kawano

Richard S Clark

Tetsuya Kawahara

Kazuo Okano

Masayuki Matsukura

Mutsuko Ono

Hiroe Minami

Hideto Ohara

Shuhei Miyazawa

Mitsuaki Miyamoto

Nobuaki Sato

Kazutoshi Miyake

Akiharu Kajiwara

Ieharu Hishinuma

Norio Karibe

Hiroshi Tanaka

Masanobu Shinoda

Fumiyoshi Matsuura

Satoshi Katayama

Makoto Kotake

Yasutaka Takase

Taro Terauchi

Tadashi Nagakura

Toshiyuki Matsuoka

Shuichi Suzuki

Katsuhiro Moriya

Motoji Kogushi

Akifumi Kimura

Toshinobu Kunii

Osamu Ito

Kohtaro Kodama

Hiroko Kobayashi

Manabu Shirato

Ken-ichi Chiba

Naoto Ono

Mikio Takeda

Syuhei Miyazawa

Yoshiaki Oohashi

Yoshinori Takahashi

Hironori Ikuta

Kenzo Muramoto

Motohiro Soejima

Tsutomu Kawata

Ichiro Yoshida

Junichi Kamata

Eriko Doi

Noboru Yamamoto

Norihito Ohi

Hiromitsu Yokohama

Tasuku Ishida

Takashi Musha

Nobuyuki Kurusu

Daiju Hasegawa

Mutsuko Tabata

Masayoshi Ohkuro

Tohru Arai

Takashi Musya

Tsutomu Kawada

Miyuki Ohkubo

Osamu Takenaka

Jiro Sonoda

Ken-Ichi Chiba

Keni-Ichi Chiba

Takashii Musha

Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like. wherein Q represents ethylene, etc., R, Rand Rrepresent hydrogen, etc., Xrepresents Calkylene, etc., Xrepresents Calkylene, etc., Arepresents a 5- to 6-membered heterocyclic group, etc., and Arepresents Caryl, etc.

Bicycloamine derivatives

Compounds represented by the following general formula: [wherein X, X, Xand Xeach independently represent a single bond, Calkylene, etc.; Arepresents optionally substituted phenyl, etc.; Arepresents an optionally substituted 5- to 7-membered heterocyclic group containing &#x2014;C(=Q)- (wherein Qrepresents oxygen, sulfur or &#x2550;N&#x2014;R(wherein Rrepresents hydrogen or Calkyl)) and nitrogen, etc.; and Zrepresents piperidin-diyl, etc.],salts thereof and hydrates of the foregoing.

Nitrogen containing heterocyclic compounds and medicines containing the same

A 2-iminoimidazole derivative represented by the formula: {wherein R, Rand Rrepresent hydrogen, optionally substituted Calkyl, etc.; Rrepresents hydrogen, Calkyl, Calkyloxycarbonyl, etc.; Yrepresents a single bond, &#x2014;CH&#x2014;, etc.; Yrepresents a single bond, &#x2014;CO&#x2014;, etc.; and Ar represents hydrogen, a group represented by the formula: [wherein R&#x2013;Rrepresent hydrogen, Calkyl, hydroxyl, Calkoxy, etc., and Rand Ror Rand Rmay bond together to form a 5- to 8-membered heterocycle], etc.}or salt thereof.

2-iminoimidazole derivatives (2)

A 2-iminopyrrolidine derivative represented by the formula: {wherein ring B represents a benzene ring, pyridine ring, etc.; R&#x2013;Rrepresent hydrogen, halogen, Calkyl, etc.; Rrepresents hydrogen, Calkyl, Calkoxy-Calkyl, etc.; Rrepresents hydrogen, Calkyl, Calkyloxycarbonyl, etc.; Yrepresents a single bond, &#x2014;CH&#x2014;, etc.; Yrepresents a single bond, &#x2014;CO&#x2014;, etc.; and Ar represents hydrogen, a group represented by the formula: [wherein R&#x2014;Rrepresent hydrogen, Calkyl, hydroxyl, Calkoxy, etc.; and Rand Ror Rand Rmay bond together to form a 5- to 8-membered heterocyclic ring], etc.},or a salt thereof.

2-iminopyrrolidine derivatives

The present invention provides compounds represented by the following formula:wherein X, X, Xand Xeach independently represents a single bond, Calkylene, etc.; Arepresents optionally substituted phenyl, etc.; Arepresents an optionally substituted 5- to 7-membered heterocyclic group containing &#x2014;C(&#x2550;Q)&#x2014;, Qwherein represents oxygen, sulfur or &#x2550;N&#x2014;R, wherein Rrepresents hydrogen or Calkyl etc.; and Zrepresents piperidin-diyl, ect, salts thereof and hydrates of the foregoing.

Piperidine compound and pharmaceutical composition thereof

Phthalazine compounds and therapeutic agents for erectile dysfunction

Benzopiperidine derivatives

Phthalazine derivatives and remedies for erectile dysfunction

Fused pyridazine compounds

Anthranilic acid derivatives

A butenoic or propenoic acid derivative having the following formula in which G is an aryl or a heterocyclic ring, R11 and R12 are hydroben or an alkyl, X is sulfur or oxygen, R2 and R3 are hydrogen, an substituent such as an alkyl and J is pyridyl or phenyl having substituents and a heterocyclic ring may be formed between R2, R3 and J is provided here and is useful in the pharmacological field. ##STR1##

Butenoic or propenoic acid derivative

To provide a novel cyclohexane derivative, a cyclohexane derivative is defined by the formula (I) or a pharmacologically acceptable salt thereof: ##STR1## (wherein R.sup.1 and R.sup.2 may be the same or different from each other and each represents hydrogen or lower alkyl; R.sup.3 represents optionally substituted aryl or optionally substituted heteroaryl; X represents oxygen or sulfur; and Y represents a group represented by the formula: ##STR2## or the like). The compound of the present invention is useful as a preventive and therapeutic agent for diseases against which a potassium channel opening action is efficacious.

Cyclohexane derivatives

Growing community of inventors

Ushiku, Japan

Fumihiro Ozaki